Bedminster-based Matinas BioPharma Holdings has appointed Thomas Hoover to the newly created position of chief business officer.
In his new role, Hoover will be responsible for business and corporate development, strategic planning, licensing and alliance management.
“We are excited to have Thomas join our executive leadership team in this critical role during this transformational time for our company,” said Jerome D. Jabbour, CEO of Matinas. “Thomas’ extensive experience in leading commercial and corporate development functions will be invaluable as we advance our (lipid nanocrystal) platform, evaluate and execute collaborations with third parties, and make strategic decisions to expand our internal pipeline of LNC-based therapies.”
Hoover has nearly 20 years of strategic biopharmaceutical experience in business and corporate development roles, as well as new product planning across a wide range of therapeutic categories, including central nervous system, oncology, cell therapy, autoimmune diseases, endocrinology and cardiovascular/metabolic.
Hoover was most recently chief business officer and chief commercial officer at Millendo Therapeutics, a publicly traded biotechnology company, where he led corporate development efforts and defined and executed commercial strategy. Prior to that role, he was vice president of corporate development and new product planning for Sunovion (formerly Sepracor Inc.). Earlier in his career, Hoover held strategy positions of increasing responsibility at GlaxoSmithKline, and began his pharmaceutical career at the Boston Consulting Group.
